Pharma Focus Asia

Merck Serono to invest €65 million for Biopharmaceutical R&D facility expansion in Germany


Merck Serono, the biopharmaceutical business of Merck, announced the expansion of its R&D facility in Darmstadt, Germany with an investment of €65 million.


Merck is investing €65 million in a new laboratory building that will span more than 16,000 square meters and accommodate approximately 200 current employees whose focus will be accelerating innovation in R&D.

The new building will unite different functions within R&D Discovery Technologies at Merck Serono, including Molecular Pharmacology, Medicinal Chemistry, Computational Chemistry, Molecular Interactions and Biophysics, Protein Engineering and Antibody Technologies, and Protein and Cell Sciences.

With approximately 2,000 scientific and clinical development professionals working across four R&D hubs - Darmstadt, Germany, the largest R&D site; Boston, US; Tokyo, Japan; and Beijing, China - Merck Serono endeavors to make a meaningful difference in the lives of people with serious medical needs. The core areas of R&D focus for Merck Serono are oncology, immuno-oncology, and immunology.


Company NameMerck Serono
LocationDarmstadt, Germany
TypeR&D Facility Expansion
Estimated Cost€65 million
Laboratory Building CompletionFall Of 2017


magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference